SG11201810143PA - Exon skipping oligomers for muscular dystrophy - Google Patents
Exon skipping oligomers for muscular dystrophyInfo
- Publication number
- SG11201810143PA SG11201810143PA SG11201810143PA SG11201810143PA SG11201810143PA SG 11201810143P A SG11201810143P A SG 11201810143PA SG 11201810143P A SG11201810143P A SG 11201810143PA SG 11201810143P A SG11201810143P A SG 11201810143PA SG 11201810143P A SG11201810143P A SG 11201810143PA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- june
- pct
- cambridge
- suite
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3233—Morpholino-type ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662356923P | 2016-06-30 | 2016-06-30 | |
| US201662357072P | 2016-06-30 | 2016-06-30 | |
| PCT/US2017/040017 WO2018005805A1 (fr) | 2016-06-30 | 2017-06-29 | Sauts d'exons oligomères pour la dystrophie musculaire |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201810143PA true SG11201810143PA (en) | 2019-01-30 |
Family
ID=59315756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201810143PA SG11201810143PA (en) | 2016-06-30 | 2017-06-29 | Exon skipping oligomers for muscular dystrophy |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20190262375A1 (fr) |
| EP (1) | EP3478697A1 (fr) |
| JP (1) | JP2019525742A (fr) |
| KR (1) | KR20190024977A (fr) |
| CN (1) | CN109311919A (fr) |
| AU (1) | AU2017290231A1 (fr) |
| BR (1) | BR112019000006A2 (fr) |
| CA (1) | CA3025575A1 (fr) |
| CO (1) | CO2018014029A2 (fr) |
| IL (1) | IL263892A (fr) |
| MA (1) | MA45618A (fr) |
| MX (1) | MX2018016052A (fr) |
| SG (1) | SG11201810143PA (fr) |
| TW (1) | TW201811807A (fr) |
| WO (1) | WO2018005805A1 (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011057350A1 (fr) | 2009-11-12 | 2011-05-19 | The University Of Western Australia | Molécules antisens et procédés de traitement de pathologies |
| TWI541024B (zh) | 2010-09-01 | 2016-07-11 | 日本新藥股份有限公司 | 反義核酸 |
| CA3024153A1 (fr) * | 2016-06-30 | 2017-11-30 | Sarepta Therapeutics, Inc. | Procedes de preparation d'oligomeres morpholino de phosphorodiamidate |
| JP2021521794A (ja) * | 2018-04-26 | 2021-08-30 | サレプタ セラピューティクス， インコーポレイテッド | 筋ジストロフィーに対するエクソンスキッピングオリゴマーおよびオリゴマーコンジュゲート |
| US10765760B2 (en) * | 2018-05-29 | 2020-09-08 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
| US20210220386A1 (en) * | 2018-06-14 | 2021-07-22 | Sarepta Therapeutics, Inc. | Exon skipping oligomers and oligomer conjugates for muscular dystrophy |
| US20220152086A1 (en) * | 2019-03-28 | 2022-05-19 | Sarepta Therapeutics, Inc. | Methods for treating muscular dystrophy with casimersen |
| WO2021025899A1 (fr) * | 2019-08-02 | 2021-02-11 | Sarepta Therapeutics, Inc. | Compositions pharmaceutiques à base d'oligomères morpholino phosphorodiamidate |
| EP4361269A1 (fr) * | 2021-06-23 | 2024-05-01 | Nippon Shinyaku Co., Ltd. | Combinaison d'oligomères antisens |
Family Cites Families (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH445129A (fr) | 1964-04-29 | 1967-10-15 | Nestle Sa | Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé |
| US3459731A (en) | 1966-12-16 | 1969-08-05 | Corn Products Co | Cyclodextrin polyethers and their production |
| US3453257A (en) | 1967-02-13 | 1969-07-01 | Corn Products Co | Cyclodextrin with cationic properties |
| US3426011A (en) | 1967-02-13 | 1969-02-04 | Corn Products Co | Cyclodextrins with anionic properties |
| US3453259A (en) | 1967-03-22 | 1969-07-01 | Corn Products Co | Cyclodextrin polyol ethers and their oxidation products |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| ATE124999T1 (de) | 1985-03-15 | 1995-07-15 | Antivirals Inc | Immunotestmittel für polynukleotid und verfahren. |
| US5217866A (en) | 1985-03-15 | 1993-06-08 | Anti-Gene Development Group | Polynucleotide assay reagent and method |
| US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
| US5521063A (en) | 1985-03-15 | 1996-05-28 | Antivirals Inc. | Polynucleotide reagent containing chiral subunits and methods of use |
| US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5719262A (en) | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
| US5714331A (en) | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
| US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
| EP1251170A3 (fr) | 1992-07-17 | 2002-10-30 | Ribozyme Pharmaceuticals, Inc. | Procédé et réactif pour le traitement de maladies animales dépendants de NF-kappaB |
| EP0698092B1 (fr) | 1993-05-11 | 2007-07-25 | The University Of North Carolina At Chapel Hill | Oligonucleotides antisens combattant l'epissage anormal et leurs procedes d'utilisation |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| US5753613A (en) | 1994-09-30 | 1998-05-19 | Inex Pharmaceuticals Corporation | Compositions for the introduction of polyanionic materials into cells |
| US5820873A (en) | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
| IL115849A0 (en) | 1994-11-03 | 1996-01-31 | Merz & Co Gmbh & Co | Tangential filtration preparation of liposomal drugs and liposome product thereof |
| US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| US7572582B2 (en) | 1997-09-12 | 2009-08-11 | Exiqon A/S | Oligonucleotide analogues |
| WO1999042091A2 (fr) | 1998-02-19 | 1999-08-26 | Massachusetts Institute Of Technology | Compositions d'apport dans des cellules |
| US6683173B2 (en) | 1998-04-03 | 2004-01-27 | Epoch Biosciences, Inc. | Tm leveling methods |
| US6210892B1 (en) | 1998-10-07 | 2001-04-03 | Isis Pharmaceuticals, Inc. | Alteration of cellular behavior by antisense modulation of mRNA processing |
| JP2000125448A (ja) | 1998-10-14 | 2000-04-28 | Yazaki Corp | 電気接続箱 |
| JP2000256547A (ja) | 1999-03-10 | 2000-09-19 | Sumitomo Dow Ltd | 耐熱性プラスチックカード用樹脂組成物 |
| US7084125B2 (en) | 1999-03-18 | 2006-08-01 | Exiqon A/S | Xylo-LNA analogues |
| NZ514348A (en) | 1999-05-04 | 2004-05-28 | Exiqon As | L-ribo-LNA analogues |
| JP2000325085A (ja) | 1999-05-21 | 2000-11-28 | Masafumi Matsuo | デュシェンヌ型筋ジストロフィー治療剤 |
| AU2281201A (en) | 1999-12-29 | 2001-07-09 | A. James Mixson | Histidine copolymer and methods for using same |
| US7070807B2 (en) | 1999-12-29 | 2006-07-04 | Mixson A James | Branched histidine copolymers and methods for using same |
| US6653467B1 (en) | 2000-04-26 | 2003-11-25 | Jcr Pharmaceutical Co., Ltd. | Medicament for treatment of Duchenne muscular dystrophy |
| US6727355B2 (en) | 2000-08-25 | 2004-04-27 | Jcr Pharmaceuticals Co., Ltd. | Pharmaceutical composition for treatment of Duchenne muscular dystrophy |
| EP1191097A1 (fr) | 2000-09-21 | 2002-03-27 | Leids Universitair Medisch Centrum | Induction du "exon-skipping" dans des cellules eukaryotes |
| EP1446412B1 (fr) | 2001-09-04 | 2012-03-07 | Exiqon A/S | Compositions d'acides nucleiques verrouilles et utilisations |
| KR100464261B1 (ko) | 2002-01-24 | 2005-01-03 | 주식회사 파나진 | Ｐｎａ 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법 |
| KR20030084444A (ko) | 2002-04-26 | 2003-11-01 | 주식회사 파나진 | Ｐｎａ 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법 |
| US7569575B2 (en) | 2002-05-08 | 2009-08-04 | Santaris Pharma A/S | Synthesis of locked nucleic acid derivatives |
| CA2504554A1 (fr) | 2002-11-05 | 2004-05-27 | Isis Pharmaceuticals, Inc. | Composes oligomeres 2'-substitues et compositions destinees a etre utilisees dans des modulations genetiques |
| ES2566632T3 (es) | 2002-11-25 | 2016-04-14 | Masafumi Matsuo | Fármacos de ácido nucleico ENA que modifican el corte y empalme en precursores de ARNm |
| WO2004083432A1 (fr) | 2003-03-21 | 2004-09-30 | Academisch Ziekenhuis Leiden | Modulation de la reconnaissance d'exons dans le pre-arnm par interference avec la structure d'arn secondaire |
| US7211668B2 (en) | 2003-07-28 | 2007-05-01 | Panagene, Inc. | PNA monomer and precursor |
| EP1766010B1 (fr) | 2004-06-28 | 2011-02-16 | The University Of Western Australia | Oligonucléotides antisens permettant d'induire un saut d'exon et leurs procédés d'utilisation |
| WO2006112705A2 (fr) | 2005-04-22 | 2006-10-26 | Academisch Ziekenhuis Leiden | Modulation de la reconnaissance d'exon dans un pre-arnm par interference avec la liaison de proteines sr et interference avec une structure d'arn secondaire |
| EP1951872A2 (fr) | 2005-11-10 | 2008-08-06 | The University of North Carolina at Chapel Hill | Oligomères permutant l'épissage destinés à la superfamille des récepteurs tnf et leur utilisation lors de traitements de maladies |
| US20090173556A1 (en) | 2006-05-17 | 2009-07-09 | Svetlana Anatolevna Sokolova | Transport Means |
| AU2008273094B2 (en) | 2007-07-12 | 2013-05-09 | Prosensa Technologies B.V. | Molecules for targeting compounds to various selected organs, tissues or tumor cells |
| NZ584793A (en) | 2007-10-26 | 2012-05-25 | Academisch Ziekenhuis Leiden | Means and methods for counteracting muscle disorders |
| WO2010050801A1 (fr) | 2008-10-27 | 2010-05-06 | Prosensa Technologies B.V. | Procédés et moyens d’induction du saut de l’exon 45 dans l’arn pré-messager du gène de la dystrophie musculaire de duchenne |
| US8076476B2 (en) | 2007-11-15 | 2011-12-13 | Avi Biopharma, Inc. | Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits |
| US8299206B2 (en) | 2007-11-15 | 2012-10-30 | Avi Biopharma, Inc. | Method of synthesis of morpholino oligomers |
| WO2009127230A1 (fr) | 2008-04-16 | 2009-10-22 | Curevac Gmbh | Arn(m) modifié pour supprimer ou éviter une réponse immunostimulante et composition immunosuppressive |
| EP2119783A1 (fr) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Procédé pour l'omission efficace de l'exon (44) dans la dystrophie musculaire de Duchenne et moyens connexes |
| CN102203253B (zh) | 2008-10-24 | 2016-04-06 | 萨雷普塔治疗公司 | 用于dmd的多外显子跳跃组合物 |
| US9394333B2 (en) | 2008-12-02 | 2016-07-19 | Wave Life Sciences Japan | Method for the synthesis of phosphorus atom modified nucleic acids |
| JP2012523225A (ja) | 2009-04-10 | 2012-10-04 | アソシアシオン・アンスティテュ・ドゥ・ミオロジー | 疾患の処置のためのトリシクロ−ｄｎａアンチセンスオリゴヌクレオチド、組成物及び方法 |
| NZ595955A (en) | 2009-04-24 | 2012-10-26 | Prosensa Technologies Bv | Oligonucleotide comprising an inosine for treating dmd |
| KR101885383B1 (ko) | 2009-07-06 | 2018-08-03 | 웨이브 라이프 사이언시스 리미티드 | 신규한 핵산 프로드러그 및 그의 사용 방법 |
| US8470987B2 (en) | 2009-09-16 | 2013-06-25 | Chiralgen, Ltd. | Protective group for synthesis of RNA and derivative |
| WO2011057350A1 (fr) * | 2009-11-12 | 2011-05-19 | The University Of Western Australia | Molécules antisens et procédés de traitement de pathologies |
| KR102095478B1 (ko) * | 2010-05-28 | 2020-04-01 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체 |
| TWI541024B (zh) | 2010-09-01 | 2016-07-11 | 日本新藥股份有限公司 | 反義核酸 |
| US10428019B2 (en) | 2010-09-24 | 2019-10-01 | Wave Life Sciences Ltd. | Chiral auxiliaries |
| EP2672977A1 (fr) | 2011-02-08 | 2013-12-18 | The Charlotte-Mecklenburg Hospital Authority d/b/a Carolina Healthcare System | Oligonucléotides antisens |
| EP2704749A1 (fr) * | 2011-05-05 | 2014-03-12 | Sarepta Therapeutics, Inc. | Conjugués peptides/oligonucléotides |
| US9607308B2 (en) | 2011-06-29 | 2017-03-28 | American Express Travel Related Services Company, Inc. | Spend based digital ad targeting and measurement |
| PL2581448T3 (pl) | 2011-10-13 | 2015-08-31 | Association Inst De Myologie | Tricyklo-tiofosforanowy DNA |
| CN108486116A (zh) * | 2011-12-28 | 2018-09-04 | 日本新药株式会社 | 反义核酸 |
| JP2015509922A (ja) | 2012-01-27 | 2015-04-02 | プロセンサ テクノロジーズ ビー．ブイ．Ｐｒｏｓｅｎｓａ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｂ．Ｖ． | デュシェンヌ型及びベッカー型筋ジストロフィーの治療のための改善された特徴を有するｒｎａ調節オリゴヌクレオチド |
| DE102012101676A1 (de) | 2012-02-29 | 2013-08-29 | Klaus-Dieter Rösler | Verfahren und Vorrichtung zum Bearbeiten von Formularen mit einer Datenverarbeitungsanlage |
| RU2674600C2 (ru) | 2012-07-03 | 2018-12-11 | Просенса Текнолоджиз Б.В. | Олигонуклеотид для лечения пациентов с мышечной дистрофией |
| ES2940887T3 (es) | 2012-07-13 | 2023-05-12 | Wave Life Sciences Ltd | Método de preparación de oligonucleótidos quirales |
| PL2872485T3 (pl) | 2012-07-13 | 2021-05-31 | Wave Life Sciences Ltd. | Asymetryczna grupa pomocnicza |
| KR20150099804A (ko) | 2012-12-20 | 2015-09-01 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 근위축증을 치료하기 위한 개선된 엑손 스키핑 조성물 |
| NZ631245A (en) * | 2013-03-14 | 2017-09-29 | Sarepta Therapeutics Inc | Exon skipping compositions for treating muscular dystrophy |
| EP2970964B8 (fr) * | 2013-03-14 | 2019-03-06 | Sarepta Therapeutics, Inc. | Compositions de sauts d'exon pour le traitement de la dystrophie musculaire |
| KR20200139271A (ko) * | 2013-03-15 | 2020-12-11 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 근육 이영양증의 치료를 위한 개선된 조성물 |
| EP3095461A4 (fr) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Adjuvant d'acide nucléique chiral possédant une activité d'induction d'immunité, et activateur d'induction d'immunité |
| US10322173B2 (en) | 2014-01-15 | 2019-06-18 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
| JPWO2015108048A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
| EP3094728B1 (fr) | 2014-01-16 | 2022-03-09 | Wave Life Sciences Ltd. | Conception chirale |
| PT3118311T (pt) | 2014-03-12 | 2019-02-15 | Nippon Shinyaku Co Ltd | Ácido nucleico anti-sentido |
| BR122020020864B1 (pt) | 2014-06-17 | 2022-06-21 | National Center Of Neurology And Psychiatry | Oligômero antissentido, composição farmacêutica e uso de um oligômero antissentido ou um sal ou hidrato farmaceuticamente aceitável do mesmo |
| MA45819A (fr) * | 2015-10-09 | 2018-08-15 | Sarepta Therapeutics Inc | Compositions et méthodes pour traiter la dystrophie musculaire de duchenne et troubles associés |
-
2017
- 2017-06-29 WO PCT/US2017/040017 patent/WO2018005805A1/fr unknown
- 2017-06-29 CN CN201780038876.7A patent/CN109311919A/zh active Pending
- 2017-06-29 US US16/312,803 patent/US20190262375A1/en not_active Abandoned
- 2017-06-29 EP EP17737999.7A patent/EP3478697A1/fr not_active Withdrawn
- 2017-06-29 KR KR1020197002453A patent/KR20190024977A/ko not_active Application Discontinuation
- 2017-06-29 JP JP2018567259A patent/JP2019525742A/ja active Pending
- 2017-06-29 MA MA045618A patent/MA45618A/fr unknown
- 2017-06-29 BR BR112019000006-2A patent/BR112019000006A2/pt not_active Application Discontinuation
- 2017-06-29 TW TW106121834A patent/TW201811807A/zh unknown
- 2017-06-29 CA CA3025575A patent/CA3025575A1/fr not_active Abandoned
- 2017-06-29 AU AU2017290231A patent/AU2017290231A1/en not_active Abandoned
- 2017-06-29 MX MX2018016052A patent/MX2018016052A/es unknown
- 2017-06-29 SG SG11201810143PA patent/SG11201810143PA/en unknown
-
2018
- 2018-12-21 CO CONC2018/0014029A patent/CO2018014029A2/es unknown
- 2018-12-23 IL IL263892A patent/IL263892A/en unknown
-
2020
- 2020-07-28 US US16/941,318 patent/US20210187003A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2018016052A (es) | 2019-05-02 |
| US20190262375A1 (en) | 2019-08-29 |
| WO2018005805A1 (fr) | 2018-01-04 |
| CN109311919A (zh) | 2019-02-05 |
| CA3025575A1 (fr) | 2018-01-04 |
| KR20190024977A (ko) | 2019-03-08 |
| JP2019525742A (ja) | 2019-09-12 |
| IL263892A (en) | 2019-01-31 |
| US20210187003A1 (en) | 2021-06-24 |
| EP3478697A1 (fr) | 2019-05-08 |
| BR112019000006A2 (pt) | 2019-04-16 |
| MA45618A (fr) | 2019-05-08 |
| CO2018014029A2 (es) | 2019-03-18 |
| TW201811807A (zh) | 2018-04-01 |
| AU2017290231A1 (en) | 2019-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201810143PA (en) | Exon skipping oligomers for muscular dystrophy | |
| SG11201811491YA (en) | Quinazoline and indole compounds to treat medical disorders | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
| SG11201809064QA (en) | Chimeric neurotoxins | |
| SG11201810579YA (en) | Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders | |
| SG11201907034PA (en) | Methods of treating influenza | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201804934PA (en) | Novel Compounds | |
| SG11201804647TA (en) | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
| SG11201901834WA (en) | Micrornas as biomarkers for endometriosis | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201407898WA (en) | Electrode testing apparatus | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201909807TA (en) | Methods of manufacturing of niraparib | |
| SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| SG11201808830YA (en) | Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders | |
| SG11201404836QA (en) | Long-acting coagulation factors and methods of producing same | |
| SG11201804856VA (en) | C-terminal lysine conjugated immunoglobulins | |
| SG11201903012RA (en) | Anti-c1s antibodies and methods of use thereof |